Our Vision


Our Vision

Become the primary alternative to heart transplants with the implementation of our Total Artificial Heart.

Our  Mission

Carmat will provide cardiologists with innovative technologies that save lives and improve the quality of life for patients with advanced heart failure.

Our History


  • 31/12/2023

    CARMAT reaches the milestone of 50 implants of its Aeson® heart since inception and achieves sales of €2.8 million in 2023

  • 01/12/2023

    CARMAT launches a second production building at its Bois d'Arcy facility, increasing production capacity to 500 hearts per year.

  • 01/03/2023

    CARMAT celebrates its 15th anniversary


  • 26/12/2022

    First implant of Aeson® within the framework of the EFICAS clinical study in France. This prospective study will involve a total of 52 patients eligible for a heart transplant in France and will allow CARMAT to collect both additional data on the efficacy and safety of its artificial heart and medico-economic data to support its value proposition and the device’s reimbursement, notably in France. The study’s primary endpoint is survival for 180 days after implantation of the device without a disabling stroke, or a successful heart transplant within 180 days of implantation.

  • 21/11/2022

    Resumption of commercial implants of Aeson®. The implant was performed in a German hospital.


  • 03/12/2021

    CARMAT has voluntarily suspended, on a temporary basis, the implants of its Aeson® artificial heart.

  • 19/07/2021

    First commercial implant of Aeson® artificial heart in Europe. This implant was performed by the team headed bu heart surgeon DR. Ciro Maiello at the Azienda Ospedaliera dei Colli hospital in Naples, Italy.

  • 15/07/2021

    First human implant of Aeson® total artificial heart in the United States within the framework of the Early Feasibility Study (EFS). In accordance with the study protocol approved by the FDA, 10 transplant-eligible patients are expected to be enrolled in this trial. The primary study endpoint is patient survival at 180 days post-implant or a successful cardiac transplantation within 180 days post-implant. It is a staged study with a progress report of the first 3 patients after 60 days, before the enrollment of the next 7 patients.


  • 22/12/2020

    On December 22, 2020, CE marking obtained for the bridge to transplant (BTT) indication.

  • 12/10/2020

    The French National Authority for Health (HAS) confirmed its positive opinion regarding the financing by special exemption of the CARMAT total artificial heart within the framework of the EFICAS study, a prospective, multicenter, non-randomized study to be undertaken on 52 patients in France. Carmat has been granted €13 million in funding by the French Ministry of Health and Solidarity to conduct the EFICAS clinical study.

  • 06/08/2020

    Bridge to transplant experience published in the Journal of Heart and Lung Transplantation.

  • 05/02/2020

    Carmat received full approval from the FDA (Food & Drug Administration) to undertake a clinical feasibility study in the United States on 10 patients eligible for a transplant. The Centers for Medicare & Medicaid Services (CMS) approved coverage of the Carmat device and routine care items and services supplied to patients within the framework of this study.


  • 31/12/2019

    Full transfer of production to the New manufacturing site in Bois d’Arcy, France.


  • 11/07/2018

    Finalization, with positive results, of the first part (cohort 1 of 10 patients) of the pivotal study. Beginning of implantations for cohort 2.


  • 31/12/2017

    Applying for CE marking and commercial authorization. The CE mark is a prerequisite to market the prosthesis in Europe. It entails conformity with the EU regulations regarding design, manufacturing and clinical evaluation. The objective of the pivotal study is to demonstrate safety and performance of the Carmat TAH.


  • 31/12/2016

    With the feasibility study relating to four patients completed, the experience gained allows Carmat to start the pivotal study, after receiving both ANSM (National agency for medicines and health product’s Safety) and CPP authorizations.


  • 31/12/2013

    Carmat obtains authorization from the ANSM to conduct a feasibility study in France involving four patients. First successful implantation performed on December 18, 2013 at the Georges Pompidou European Hospital by Professor Christian Latrémouille.


  • 31/12/2011

    Carmat presents preclinical hemocompatibility data to the 25th Annual Congress of the European Association for Cardio-Thoracic Surgery (EACTS). Carmat received approval from the CPP from the French ethical research committee.


  • 31/12/2008

    Creation of CARMAT by Matra Défense (Airbus Group), Truffle Capital and Professor Alain Carpentier.


Carmat governance ensures an effective and transparent organization for its different supervisory and operational management teams to create long-term value for all stakeholders. It includes the Management Team and the Board of Directors.

Code of ethics and business conduct

Download the Code of ethics and business conduct of Carmat


Corporate Headquarters

Immeuble l'Etendard
36 avenue de l'Europe
78140 Vélizy-Villacoublay

Manufacturing site

9 rue René Clair
78390 Bois-d'Arcy
Top of page